Abstract
Since the outbreak of SARS-CoV-2, quantitative real-time PCR and CRISPR-based methods have been increasingly used for virus detection because of their speed (1 hour) and sensitivity. However, these methods do not allow for the absolute quantification of virus particles, which could reduce the inter-lab variability and accelerate the virus research. Although there is a digital PCR-based method that has been used for absolute virus quantification, its reaction time (4 hours) is too long for widespread application. Here, we report a rapid digital CRISPR method developed for the absolute quantification of SARS-CoV-2 DNA and Epstein–Barr virus DNA in human samples that yields results within 1 hour. We validated this method using synthetic SARS-CoV-2 DNA and Epstein–Barr viral DNA and compared results with those obtained with digital PCR. Digital CRISPR allows absolute quantification of DNA with a dynamic range from 0.6 to 2027 copies/µL (R2 value > 0.98), without cross reactivity on similar virus and human background DNA. Thus, our digital CRISPR can accurately detect and quantify nucleic acid in 1h without thermal cycling, which provides a 4-fold faster alternative to digital PCR-based virus detection.
Competing Interest Statement
X.W., T.K.L., and H.Y. are co-inventors on patent filings related to the published work. T.K.L. is a co-founder of Senti Biosciences, Synlogic, Engine Biosciences, Tango Therapeutics, Corvium, BiomX, Eligo Biosciences, Bota.Bio, and Avendesora. T.K.L. also holds financial interests in nest.bio, Ampliphi, IndieBio, MedicusTek, Quark Biosciences, Personal602Genomics, Thryve, Lexent Bio, MitoLab, Vulcan, Serotiny, and Avendesora.
Funding Statement
We thank Karen Pepper (MIT) and Scott A. Rice(NTU) for careful editing and helpful comments on the manuscript. This research is supported by the National Research Foundation, Prime Minister’s Office, Singapore under its Campus for Research Excellence and Technological Enterprise (CREATE) programme, through Singapore MIT Alliance for Research and Technology (SMART): Critical Analytics for Manufacturing Personalised-Medicine (CAMP) Inter-Disciplinary Research Group.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This manuscript is a method paper using synthetic DNA. No clinical samples were used in this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
More data are included in Supplementary Materials.
